Reliance Global Group has launched LifeSci Global, a dedicated life sciences platform led by Scott Korman and David Turner, focusing on building and growing biotech companies. The platform's first investment is Innervate Radiopharmaceuticals, which develops PET imaging and therapies for neuroblastoma, with potential expansion into cardiovascular and neurodegenerative diseases. This move aligns with Reliance's strategy of active company-building rather than passive investing, aiming to create long-term value through expert leadership and targeted biotech innovation. LifeSci Global is now evaluating additional opportunities in the life sciences sector.
Eman Abio, co-founder of Mysten Labs, criticized the current crypto gas fee model as structurally flawed and limiting global growth. He explained that Sui network aims to eliminate transaction fees by releasing a free payment SDK in 2026, supporting ...
XRP has faced bearish trading for over a week, with liquidity on Binance dropping close to zero according to CryptoQuant data. This sharp decline in liquidity means fewer sell orders are available, which can reduce selling pressure and allow large bu...
The latest Star Wars movie, "The Mandalorian and Grogu," opened with an $82 million domestic debut, the weakest among recent franchise releases, falling short of the $84 million debut of 2018's "Solo." Despite this, the film is expected to surpass $1...
Iranian and U.S. diplomats met in Doha on May 25, 2026, to negotiate a peace framework focusing on Iran's uranium stockpile and control of the Strait of Hormuz. Positive signals from the talks led Brent crude oil prices to drop 4-6% to around $95-97 ...
Grupo Rotoplas, a leading water management company in the Americas, released its 2025 Sustainable Development Impact Disclosure Report (SDID). This report connects the company's business strategy with measurable outcomes aligned with the UN Sustainab...
